ACADIA Pharmaceuticals (ACAD) Competitors $21.24 -0.12 (-0.56%) Closing price 04:00 PM EasternExtended Trading$21.24 0.00 (0.00%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACAD vs. ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, BPMC, BBIO, and VRNAShould you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. ACADIA Pharmaceuticals vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Intra-Cellular Therapies (NASDAQ:ITCI) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends. Which has more volatility & risk, ITCI or ACAD? Intra-Cellular Therapies has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Does the media prefer ITCI or ACAD? In the previous week, ACADIA Pharmaceuticals had 21 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 21 mentions for ACADIA Pharmaceuticals and 0 mentions for Intra-Cellular Therapies. ACADIA Pharmaceuticals' average media sentiment score of 0.69 beat Intra-Cellular Therapies' score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Intra-Cellular Therapies Neutral ACADIA Pharmaceuticals Positive Do institutionals and insiders believe in ITCI or ACAD? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is ITCI or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 22.97% compared to Intra-Cellular Therapies' net margin of -14.07%. ACADIA Pharmaceuticals' return on equity of 17.46% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% ACADIA Pharmaceuticals 22.97%17.46%10.75% Do analysts recommend ITCI or ACAD? Intra-Cellular Therapies currently has a consensus price target of $109.70, indicating a potential downside of 16.81%. ACADIA Pharmaceuticals has a consensus price target of $27.88, indicating a potential upside of 31.24%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17ACADIA Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.71 Which has stronger valuation and earnings, ITCI or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64ACADIA Pharmaceuticals$957.80M3.71$226.45M$1.3715.50 SummaryACADIA Pharmaceuticals beats Intra-Cellular Therapies on 15 of the 17 factors compared between the two stocks. Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACAD vs. The Competition Export to ExcelMetricACADIA PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.55B$2.90B$5.49B$8.94BDividend YieldN/A2.69%5.38%4.13%P/E Ratio15.5021.3126.2119.90Price / Sales3.71277.38415.20165.00Price / Cash30.6041.8936.4957.06Price / Book4.837.518.055.38Net Income$226.45M-$55.05M$3.15B$248.50M7 Day Performance-5.60%2.44%1.93%2.99%1 Month Performance-1.07%7.32%4.91%6.03%1 Year Performance34.09%5.38%35.87%20.40% ACADIA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACADACADIA Pharmaceuticals4.6922 of 5 stars$21.24-0.6%$27.88+31.2%+33.2%$3.55B$957.80M15.50510ITCIIntra-Cellular Therapies0.908 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.8833 of 5 stars$20.68-2.3%$39.17+89.4%-16.5%$13.26B$3.12B11.752,682High Trading VolumeRDYDr. Reddy's Laboratories2.7934 of 5 stars$15.31+0.5%$16.95+10.7%-1.0%$12.78B$3.81B23.2027,811ASNDAscendis Pharma A/S3.5535 of 5 stars$175.78-0.6%$220.67+25.5%+28.4%$10.75B$393.54M-27.991,017Positive NewsVTRSViatris3.0377 of 5 stars$8.85-0.2%$10.40+17.5%-13.3%$10.39B$14.74B-2.7932,000QGENQiagen3.7647 of 5 stars$46.72-0.1%$47.74+2.2%+23.2%$10.39B$2.00B117.145,765Dividend AnnouncementMRNAModerna4.3556 of 5 stars$25.67-0.9%$46.61+81.6%-75.3%$9.93B$3.14B-2.945,800Trending NewsOptions VolumeGap UpBPMCBlueprint Medicines1.5434 of 5 stars$128.40+0.2%$128.06-0.3%+17.5%$8.29B$508.82M-51.98640High Trading VolumeBBIOBridgeBio Pharma4.7121 of 5 stars$42.17+1.1%$56.67+34.4%+69.8%$8.01B$127.42M-11.95400Analyst ForecastInsider TradeVRNAVerona Pharma PLC American Depositary Share2.5718 of 5 stars$97.05+2.9%$101.10+4.2%+483.4%$7.87B$118.54M-48.5330Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Qiagen Alternatives Moderna Alternatives Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACAD) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
